0,1,2,3,4
Table 6.5.1:  Randomised phase III controlled trials – nmCRPC,,,,
Study,Intervention,Comparison,Selection criteria,Main outcomes
"ARAMIS  2019, 2020  [1176, 1177]",ADT + darolutamide,ADT + placebo,nmCRPC;   baseline   PSA > 2 ng/mL  PSA-DT < 10 mo.,59% reduction of distant   progression or death   Median MFS: darolutamide   40.4 vs placebo 18.4 mo;  31% reduction in risk of death  HR = 0.69 (95% CI: 0.53–0.88)  p = 0.003
"PROSPER   2018, 2020  [1174, 1178]",ADT + enzalutamide,ADT + placebo,nmCRPC;   baseline    PSA > 2 ng/mL  PSA-DT < 10 mo.,71% reduction of distant   progression or death   Median MFS: enzalutamide   36.6 vs placebo 14.7 months;  27% reduction in risk of death  HR = 0.73 (95% CI: 0.61–0.89)  p = 0.001
"SPARTAN   2018, 2021  [1175, 1179]",ADT + apalutamide,ADT + placebo,nmCRPC;   baseline    PSA > 2 ng/mL  PSA-DT < 10 mo.,72% reduction of distant   progression or death  Median MFS: apalutamide    40.5 vs placebo 16.2 months;  22% reduction in risk of death  HR = 0.78 (95% CI: 0.64–0.96)  p = 0.0161
